WO2005044825A1 - Composes de silicium et utilisations de ceux-ci - Google Patents

Composes de silicium et utilisations de ceux-ci Download PDF

Info

Publication number
WO2005044825A1
WO2005044825A1 PCT/GB2004/004240 GB2004004240W WO2005044825A1 WO 2005044825 A1 WO2005044825 A1 WO 2005044825A1 GB 2004004240 W GB2004004240 W GB 2004004240W WO 2005044825 A1 WO2005044825 A1 WO 2005044825A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
trimethylsilyl
urea
phenyl
ethoxy
Prior art date
Application number
PCT/GB2004/004240
Other languages
English (en)
Inventor
John Gary Montana
Graham Andrew Showell
David Jonathan Otway
Original Assignee
Amedis Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0324581A external-priority patent/GB0324581D0/en
Priority claimed from GB0328147A external-priority patent/GB0328147D0/en
Application filed by Amedis Pharmaceuticals Ltd. filed Critical Amedis Pharmaceuticals Ltd.
Publication of WO2005044825A1 publication Critical patent/WO2005044825A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • TNF Tumour necrosis factor
  • IL-1 interleukin-1
  • proinflammatory cytokines These, along with several other related molecules, mediate the inflammatory response associated with the immunological recognition of infectious agents. The inflammatory response plays an important role in limiting and controlling pathogenic infections. Elevated levels of proinflammatory cytokines are also associated with a number of diseases of autoimmunity such as toxic shock syndrome, rheumatoid arthritis, osteoarthritis, diabetes and inflammatory bowel disease (Dinarelloef al, 1984, Rev. Infect. Disease, 6, 51 and Koch et al, 1995, J.
  • TNF also referred to in its secreted cell-free form as TNF ⁇
  • IL-1 ⁇ proinflammatory cytokines
  • TNF also referred to in its secreted cell-free form as TNF ⁇
  • IL-1 ⁇ proinflammatory cytokines
  • Inhibitors of cytokine production are expected to block inducible cyclooxygenase (COX-2) expression.
  • COX-2 expression has been shown to be increased by cytokines and it is believed to be the isoform of cyclooxygenase responsible for inflammation (O'Banion etal, 1992, Proc. Natl. Acad. Sci. U.S.A. 89, 4888).
  • inhibitors of cytokines such as IL-1 would be expected to exhibit efficacy against those disorder currently treated with COX inhibitors, such as the familiar NSAIDs. These disorders include acute and chronic pain as well as symptoms of inflammation and cardiovascular disease.
  • cytokines Elevation of several cytokines has been demonstrated during active inflammatory bowel disease (IBD) (Cominelli et al, 1996, Aliment. Pharmacol. Ther. 10, 49).
  • Proinflammatory cytokines such as TNF ⁇ and IL-1 ⁇ are also important mediators of septic shock and associated cardiopulmonary dysfunction, acute respiratory distress syndrome (ARDS) and multiple organ failure.
  • TNF ⁇ has also been implicated in cachexia and muscle degradation, associated with HIV infection (Lahdiverta et al, 1988, Amer. J. Med. 85, 289).
  • Compounds which modulate release of one or more of the aforementioned inflammatory cytokines can be useful in treating diseases associated with release of these cytokines.
  • WO-A-98/52558, WO-A-00/43384, WO-A-01/04115 and WO-A-03/005999 disclose heteroaryl urea compounds, which are indicated to be useful in treating cytokine mediated diseases.
  • WO-A-02/092576 describes diarylurea derivatives which may be useful as anti- inflammatory agents.
  • Sila-substitution (C/Si-exchange) of drugs is a relatively recent approach for searching for organo-silicon compounds which have beneficial biological properties. The approach involves the replacement of specific carbon atoms in compounds by silicon, and monitoring how the biological properties of the compounds have changed. A review of this approach is provided in Tacke and Zilch, Endeavour, New Series, 10, 191-197 (1986). Summary of the Invention A first aspect of the invention is a compound of formula (I)
  • R 1 , R 2 and R 3 are the same or different and are each alkyl, -alkyl-aryl or -alkyl-cycloalkyl; or R 1 -Si-R 2 taken together form heterocycloalkyl;
  • R 4 is aryl or heteroaryl, either of which is optionally substituted with -Y-R 5 ;
  • R 5 is alkyl, cycloalkyl, heterocycloalkyl or heteroaryl;
  • W is arylene, optionally substituted with one or more substituents selected from halogen, hydroxy, alkyl, -alkyl-aryl, -alkyl-cycloalkyl, aryl, heteroaryl, -alkyl- heteroaryl, -alkyl-heterocycloalkyl, -alkoxy-heterocycloalkyl, alkoxy, aryloxy, hydroxyalkyl, -NHC(O)-alkyl, -NHC(0)-ary
  • a compound of formula (I) for the manufacture of a medicament for the treatment or prevention of an inflammatory disease, an autoimmune disease, acute pain, chronic pain, neuropathic pain, contact dermatitis, atherosclerosis, glomerulonephritis, reperfusion injury, a bone resorption disease, asthma, stroke, myocardial infarction, thermal injury, adult respiratory distress syndrome (ARDS), multiple organ injury secondary to trauma, dermatoses with acute inflammatory components, acute purulent meningitis, necrotising entrerocolitis, a syndrome associated with hemodialysis, septic shock, leukopherisis, granulocyte transfusion, acute or chronic inflammation of the lung caused by smoke inhalation, endometriosis, Behcet's disease, uveitis, ankylosing spond
  • R 1 , R 2 and R 3 are preferably each alkyl, more preferably methyl.
  • R 4 is preferably naphthyl, indole or azaindole, any of which is optionally substituted with -Y-R 5 .
  • Y is preferably alkylene (e.g. ethylene), -O-alkyl- (e.g. -OCH 2 CH 2 -) or -heterocycloalkyl-alkyl- (e.g. -piperidinyl- methyl-).
  • R 5 is preferably morpholin-4-yl, piperidinyl, piperazinyl or pyridinyl.
  • W and X are preferably optionally substituted phenylene and oxygen respectively.
  • alkyl refers to an optionally substituted straight or branched chain alkyl moiety having from one to six carbon atoms. This term includes, for example, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl, hexyl and the like. "C,. 6 alkyl" has the same meaning.
  • the group may be substituted with one or more substituents, the substituents being the same or different and selected from hydroxy and the like.
  • Alkylene refers to a similar, divalent group.
  • alkoxy refers to a straight or branched chain alkoxy group containing one to six carbon atoms. This term includes, for example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, tert-butoxy, pentoxy, hexoxy and the like.
  • C 1-6 alkoxy has the same meaning.
  • halogen refers to F, CI, Br or I.
  • aryl as used herein refers to an optionally substituted aromatic ring system having from six to fourteen ring carbon atoms.
  • the group may be a polycyclic ring system, having two or more rings, at least one of which is aromatic. This term includes, for example, phenyl and naphthyl.
  • the group may be substituted with one or more substituents, the substituents being the same or different and selected from alkyl, cycloalkyl, halogen, hydroxy, trifluoromethyl, cyano and the like.
  • cycloalkyl refers to a saturated alicyclic moiety having from three to six carbon atoms. This term includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.
  • heterocycloalkyl refers to a saturated heterocyclic moiety having from three to seven ring carbon atoms and one or more heteroatoms selected from nitrogen, oxygen, phosphorus, sulphur and silicon. This term includes, for example, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl and the like.
  • the group may be substituted with one or more substituents, the substituents being the same or different and selected from alkyl, alkoxy, hydroxy, oxo and the like.
  • substituents being the same or different and selected from alkyl, alkoxy, hydroxy, oxo and the like.
  • heteroaryl refers to an aromatic ring system having from five to ten ring atoms, at least one of which is selected from nitrogen, oxygen and sulphur.
  • the group may be a polycyclic ring system, having two or more rings, at least one of which is aromatic. This term includes, for example, furanyl, thiophenyl, pyridyl, indolyl, quinolyl and the like.
  • the group may be substituted with one or more substituents, the substituents being the same or different and selected from alkyl, cycloalkyl, halogen, hydroxy, trifluoromethyl, cyano and the like.
  • Preferred compounds of the invention include: 1-(2-tert-butyl-5-trimethylsilyl-phenyl)-3-[4-(4-morpholin-4-ylmethyl- piperidin-1 -yl)-naphthalen-1 -yl]-urea; 1-(2-methyl-5-trimethylsilyl-phenyl)-3-[4-(4-piperidin-1-ylmethyl-piperidin- 1-yl)-naphthalen-1-yl]-urea; 1-(5-tert-butyl-2-trimethylsilyl-phenyl)-3-[4-(4-morpholin-4-ylmethyl- piperidin-1 -yl)-naphthalen-1 -yl]-urea; 1-(2-methyl-5-trimethyls
  • Compounds of the invention may be chiral. They may be in the form of a single enantiomer or diastereomer, or a racemate.
  • the compounds may exist in isomeric or tautomeric form; such isomers or tautomers form part of the present invention.
  • compounds of the invention such as those comprising a pyridyl or morpholinyl group, may be in the form of an N- oxide; such N-oxides also form part of the present invention.
  • the compounds of the invention may be prepared in racemic form, or prepared in individual enantiomeric form by specific synthesis or resolution as will be appreciated in the art.
  • the compounds may, for example, be resolved into their enantiomers by standard techniques, such as the formation of diastereomeric pairs by salt formation with an optically active acid followed by fractional crystallisation and regeneration of the free base.
  • the enantiomers of the novel compounds may be separated by HPLC using a chiral column.
  • a compound of the invention may be in a protected amino or protected carboxy form.
  • protected amino and “protected carboxy” as used herein refer to amino and carboxy groups which are protected in a manner familiar to those skilled in the art.
  • an amino group can be protected by a benzyloxycarbonyl, tert-butoxycarbonyl, acetyl or like group, or in the form of a phthalimido or like group.
  • a carboxyl group can be protected in the form of a readily cleavable ester such as the methyl, ethyl, benzyl or tert-butyl ester.
  • Some compounds of the formula may exist in the form of solvates, for example hydrates, which also fall within the scope of the present invention.
  • Compounds of the invention may be in the form of pharmaceutically acceptable salts, for example, addition salts of inorganic or organic acids.
  • Such inorganic acid addition salts include, for example, salts of hydrobromic acid, hydrochloric acid, nitric acid, phosphoric acid and sulphuric acid.
  • Organic acid addition salts include, for example, salts of acetic acid, benzenesulphonic acid, benzoic acid, camphorsulphonic acid, citric acid, 2-(4-chlorophenoxy)-2- methylpropionic acid, 1 ,2-ethanedisulphonic acid, ethanesulphonic acid, ethylenediaminetetraacetic acid (EDTA), fumaric acid, glucoheptonic acid, gluconicacid, glutamicacid, N-glycolylarsanilicacid, 4-hexylresorcinol, hippuric acid, 2-(4-hydroxybenzoyl)benzoicacid, 1-hydroxy-2-naphthoicacid, 3-hydroxy- 2-naphthoic acid, 2-hydroxyethanesulphonic acid, lactobi
  • salts may be prepared by reacting the compound with a suitable acid in a conventional manner.
  • a compound of the invention may be prepared by any suitable method known in the art and/or by the following process (for suitable procedures see Regan et al, J. Med. Chem. 2002, 45, 2994; Shvedov et al, Zhumal Organicheskoi Khimii, 1969, 5, 2221; WO-A-03/087087; GB-A-0781390; and US3300506):
  • the compounds of the invention may be used in the treatment of numerous ailments, conditions and diseases including, but not limited thereto, inflammatory diseases (e.g. rheumatoid arthritis, multiple sclerosis, Guillain- Barre syndrome, Crohn's disease, ulcerative colitis, psoriasis, graft versus host disease, systemic lupus, erythematosus or insulin-dependent diabetes mellitus), autoimmune diseases (e.g.
  • toxic shock syndrome osteoarthritis, diabetes or inflammatory bowel disease
  • acute pain chronic pain
  • neuropathic pain contact dermatitis, atherosclerosis, glomerulonephritis, reperfusion injury, bone resorption diseases, asthma, stroke, myocardial infarction, thermal injury, adult respiratory distress syndrome (ARDS), multiple organ injury secondary to trauma, dermatoses with acute inflammatory components, acute purulent meningitis, necrotisingentrerocolitis, syndromes associated with hemodialysis, septic shock, leukopherisis, granulocyte transfusion, acute or chronic inflammation of the lung caused by smoke inhalation, endometriosis, Behcet's disease, uveitis, ankylosing spondylitis, pancreatitis, cancer, Lyme disease, restenosis following percutaneous transluminal coronary angioplasty, Alzheimer's disease, traumatic arthritis, sepsis, chronic obstructive pulmonary disease or congestive heart failure.
  • cancer refers to any disease or condition characterised by uncontrolled, abnormal growth of cells and includes all known types of cancer, for example cancer of the bladder, breast, colon, brain, bone, head, blood, eye, neck, skin, lungs, ovaries, prostate and rectum; digestive, gastrointestinal, endometrial, hematological, AIDS-related, muscoskeletal, neurological and gynecological cancers; lympomas, melanomas and leukemia.
  • the active compound may be administered orally, rectally, parenterally, by inhalation (pulmonary delivery), topically, ocularly, nasally, or to the buccal cavity. Oral administration is preferred.
  • compositions of the present invention may take the form of any of the known pharmaceutical compositions for such methods of administration.
  • the compositions may be formulated in a manner known to those skilled in the art so as to give a controlled release, for example rapid release or sustained release, of the compounds of the present invention.
  • Pharmaceutically acceptable carriers suitable for use in such compositions are well known in the art.
  • the compositions of the invention may contain 0.1-99% by weight of active compound.
  • the compositions of the invention are generally prepared in unit dosage form. Preferably, a unit dose comprises the active ingredient in an amount of 1-500 mg.
  • the excipients used in the preparation of these compositions are the excipients known in the art. Appropriate dosage levels may be determined by any suitable method known to one skilled in the art.
  • compositions for oral administration are preferred compositions of the invention and there are known pharmaceutical forms for such administration, for example tablets, capsules, granules, syrups and aqueous or oily suspensions.
  • composition containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
  • Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions, and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavouring agents, colouring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
  • excipients may be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example corn starch or alginic acid; binding agents, for example starch gelatin, acacia, microcrystalline cellulose or polyvinyl pyrrolidone; and lubricating agents, for example magnesium stearate, stearic acid or talc.
  • the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.
  • Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
  • Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
  • excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinyl pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long-chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids, for example polyoxyethylene sorbitan monooleate.
  • dispersing or wetting agents may be a naturally occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long-chain aliphatic alcohols, for example heptadecaethyleneoxycetanol,
  • the aqueous suspensions may also contain one or more preservatives, for example ethyl or n-propyl p- hydroxybenzoate, one or more colouring agents, one or more flavouring agents, and one or more sweetening agents, such as sucrose or saccharin.
  • Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
  • the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents, such as those set forth above, and flavouring agents may be added to provide a palatable oral preparation.
  • compositions may be preserved by the addition of an antioxidant such as ascorbic acid.
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable sweetening, flavouring and colouring agents may also be present.
  • the pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions.
  • the oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin, or mixtures of these.
  • Suitable emulsifying agents may be naturally occurring gums, for example gum acacia or gum tragacanth, naturally occurring phosphatides, for example soya bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate.
  • the emulsions may also contain sweetening and flavouring agents. Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose.
  • Such formulations may also contain a demulcent, a preservative and flavouring and colouring agents.
  • the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
  • the sterile injectable preparation may also be in a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3- butanediol.
  • the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid, find use in the preparation of injectables.
  • the compounds of the invention may also be administered in the form of suppositories for rectal administration of the drug.
  • These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.
  • Compositions for topical administration are also suitable for use in the invention.
  • the pharmaceutically active compound may be dispersed in a pharmaceutically acceptable cream, ointment or gel.
  • a suitable cream may be prepared by incorporating the active compound in a topical vehicle such as light liquid paraffin, dispersed in a aqueous medium using surfactants.
  • An ointment may be prepared by mixing the active compound with a topical vehicle such as a mineral oil or wax.
  • a gel may be prepared by mixing the active compound with a topical vehicle comprising a gelling agent.
  • Topically administrable compositions may also comprise a matrix in which the pharmaceutically active compounds of the present invention are dispersed so that the compounds are held in contact with the skin in order to administer the compounds transdermally.
  • the following Example illustrates the invention.
  • Step 1 (4-Methoxyphenyl)trimethylsilane To a solution of 4-bromoanisole (3.3 ml, 26.7 mmol) in tetrahydrofuran (100ml) at -78 °C was added n-butyl lithium (16.7 ml, 1.6 M solution in hexanes, 26.7 mmol) dropwise and the reaction stirred at this temperature for 15 minutes. Trimethylsilyl chloride (3.4 ml, 26.7 mmol) was then added and the reaction allowed to warm to ambient temperature. The solution was concentrated under reduced pressure and the residue taken up in ethyl acetate and washed with water.
  • Step 2 (4-Methoxy-3-nitrophenyl)trimethylsilane
  • nitronium tetrafluoroborate 2.2 g, 16.8 mmol
  • the deep brown solution was stirred at this temperature for 20 minutes, water was added and the reaction extracted with ethyl acetate, dried (magnesium sulphate) and concentrated under reduced pressure to give the crude product.
  • Purification by column chromatography (silica; petroleum ether to 85:15 petroleum ether/ethyl acetate) gave the title compound as a yellow crystalline solid (1.25 g, 34%).
  • Step 4 tert-Butyl 1-hydroxynaphthalen-4-ylcarbamate
  • 4-amino-1 -naphthol hydrochloride 5.3 g, 27.1 mmol
  • d ⁇ -tert- butyl dicarbonate 6.5 g, 29.8 mmol
  • lithium hydroxide 0.65 g, 27.1 mmol
  • Step 5 tert-Butyl 1-(2-morpholinoethoxy)naphthalene-4-yI carbamate
  • a mixture of the foregoing naphthol (4.2 g, 16.2 mmol), 4-(2- chloroethyl)morpholine hydrochloride (3.3 g, 17.8 mmol) and potassium carbonate (9 g, 64.9 mmol) in acetonitrile (150 ml) was heated at 80 °C for 16 hours, cooled to room temperature, and diluted with ethyl acetate and water.
  • Step 6 4-(2-morpholinoethoxy)naphthalene-1-amine dihydrochloride tert-Butyl 1 -(2-morpholinoethoxy)naphthalene-4-yl carbamate (7.6 g, 20.4 mmol) was stirred with hydrochloric acid (75 ml, 4M solution in dioxane) at ambient temperature for 20 hours. The volatiles were removed under reduced pressure to give the title compound as a pink solid (7.8g).
  • Step 7 1 -(2-Methoxy-5-trimethylsilyl-phenyl)-3-[4-(2-mo olin-4-yl-ethoxy)- naphthalen-1 -yl]-urea
  • 2-methoxy-5-(trimethylsilyl)benzamine (242 mg, 1.2 mmol) in dichloromethane (30 ml) and saturated aqueous sodium bicarbonate (30 ml) at 0 °C was added phosgene (2.6 ml of a 20% solution in toluene, 5 mmol) and the mixture stirred at this temperature for 30 minutes.

Abstract

L'invention concerne un composé représenté par la formule (1) dans laquelle R1, R2 et R3 sont identiques ou différents et représentent chacun alkyle, -alkyl-aryle ou -alkyl-cycloalkyle, ou R1-Si-R2 pris ensemble forment hétérocycloalkyle, R4 représente aryle ou hétéroaryle, chacun étant éventuellement substitué avec -Y-R5, R5 représente alkyle, cycloalkyle, hétérocycloalkyle ou hétéroaryle, W représente arylène, éventuellement substitué avec au moins un substituant choisi dans le groupe comprenant halogène, hydroxy, alkyle, -alkyl-aryle, -alkyl-cycloalkyle, aryle, hétéroaryle, -alkyl-hétéroaryle, -alkyl-hétérocycloalkyle, -alcoxy-hétérocycloalkyle, alcoxy, aryloxy, hydroxyalkyle, -NHC(O)-alkyle, -NHC(O)-aryle, -NHS(O)2-alkyle, -NHS(O)2-aryle, cyano et -Si(R1)(R2)(R3), X représente oxygène ou soufre, Y représent une liaison, -NH-, -O-, -S-, -Si(R6)(R7)-, alkylène, -O-alkyl-, -S-alkyl-, -NH alkyl-, -Si(R6)(R7)-alkyl-, hétérocycloalkylène ou -hétérocycloalkyl-alkyl-, et R6 et R7 sont identiques ou différents et représentent chacun alkyle, -alkyl-aryle ou -alkyl-cycloalkyle, ou R6-Si-R7 pris ensemble forment hétérocycloalkyle, ou un sel pharmaceutiquement acceptable de ce composé ou un promédicament pouvant être oxydé ou hydrolysé pour former un composé tel que défini ci-dessus.
PCT/GB2004/004240 2003-10-21 2004-10-07 Composes de silicium et utilisations de ceux-ci WO2005044825A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0324581A GB0324581D0 (en) 2003-10-21 2003-10-21 Compounds and their use
GB0324581.8 2003-10-21
GB0328147.4 2003-12-04
GB0328147A GB0328147D0 (en) 2003-12-04 2003-12-04 Compounds and their use

Publications (1)

Publication Number Publication Date
WO2005044825A1 true WO2005044825A1 (fr) 2005-05-19

Family

ID=34575751

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/004240 WO2005044825A1 (fr) 2003-10-21 2004-10-07 Composes de silicium et utilisations de ceux-ci

Country Status (1)

Country Link
WO (1) WO2005044825A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521435B2 (en) * 2005-02-18 2009-04-21 Pharma Diagnostics, N.V. Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same
US8927563B2 (en) 2013-04-02 2015-01-06 Respivert Limited Kinase inhibitor
US9499486B2 (en) 2014-10-01 2016-11-22 Respivert Limited Kinase inhibitor
US9783556B2 (en) 2012-08-29 2017-10-10 Respivert Limited Kinase inhibitors
US9790209B2 (en) 2012-08-29 2017-10-17 Respivert Limited Kinase inhibitors
US9796742B2 (en) 2012-08-29 2017-10-24 Respivert Limited Kinase inhibitors
US9890185B2 (en) 2013-12-20 2018-02-13 Respivert Limited Urea derivatives useful as kinase inhibitors
US10072034B2 (en) 2016-04-06 2018-09-11 Respivert Limited Kinase inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092576A1 (fr) * 2001-05-16 2002-11-21 Boehringer Ingelheim Pharmaceuticals, Inc. Derives de diaryluree utilisables en tant qu'agents anti-inflammatoires

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092576A1 (fr) * 2001-05-16 2002-11-21 Boehringer Ingelheim Pharmaceuticals, Inc. Derives de diaryluree utilisables en tant qu'agents anti-inflammatoires

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 54, no. 2, 25 January 1960, Columbus, Ohio, US; abstract no. 358a, SAKATA, YASUTADA ET AL: "Syntheses of organosilicon compounds. II. Synthesis of p-trimethylsilylaniline" XP002311361 *
YAKUGAKU ZASSHI , 79, 875-7 CODEN: YKKZAJ; ISSN: 0031-6903, 1959 *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521435B2 (en) * 2005-02-18 2009-04-21 Pharma Diagnostics, N.V. Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same
US9783556B2 (en) 2012-08-29 2017-10-10 Respivert Limited Kinase inhibitors
US9790209B2 (en) 2012-08-29 2017-10-17 Respivert Limited Kinase inhibitors
US9796742B2 (en) 2012-08-29 2017-10-24 Respivert Limited Kinase inhibitors
US8927563B2 (en) 2013-04-02 2015-01-06 Respivert Limited Kinase inhibitor
US9481648B2 (en) 2013-04-02 2016-11-01 Respivert Limited Kinase inhibitors
US10435361B2 (en) 2013-04-02 2019-10-08 Topivert Pharma Limited Kinase inhibitors
US9790174B2 (en) 2013-04-02 2017-10-17 Respivert Limited Kinase inhibitors
US9890185B2 (en) 2013-12-20 2018-02-13 Respivert Limited Urea derivatives useful as kinase inhibitors
US9751837B2 (en) 2014-10-01 2017-09-05 Respivert Limited Kinase inhibitors
US9822076B2 (en) 2014-10-01 2017-11-21 Respivert Limited Kinase inhibitor
US10125100B2 (en) 2014-10-01 2018-11-13 Respivert Limited Kinase inhibitors
US10392346B2 (en) 2014-10-01 2019-08-27 Topivert Pharma Limited Kinase inhibitors
US9499486B2 (en) 2014-10-01 2016-11-22 Respivert Limited Kinase inhibitor
US10941115B2 (en) 2014-10-01 2021-03-09 Oxular Acquisitions Limited Kinase inhibitors
US10072034B2 (en) 2016-04-06 2018-09-11 Respivert Limited Kinase inhibitors
US10442828B2 (en) 2016-04-06 2019-10-15 Topivert Pharma Limited Kinase inhibitors

Similar Documents

Publication Publication Date Title
WO2004113352A1 (fr) Derives d'heterocyclyluree silyles inhibiteurs des cytokines
JP4812745B2 (ja) アリール及びヘテロアリールピペリジンカルボン酸誘導体、その製造並びにｆａａｈ酵素阻害剤としてのその使用
US5919932A (en) Biphenylamide derivatives as 5HT1D antagonists
US5180723A (en) Certain sulfonamide heterobicyclic platelet activating factor antagonists
US20110009365A1 (en) Derivatives of indole-2-carboxamides and of azaindole-2-carboxamides substituted with a silanyl group, preparation thereof and therapeutic use thereof
JPH0649027A (ja) インドール誘導体
KR20000010751A (ko) 치환된 인다졸 유도체, 및 포스포디에스테라제 4형 및 종양 괴사 인자 형성의 억제제로서의 그의 용도
JP2007505075A (ja) キノリン化合物およびそれを含む医薬組成物
KR20010094731A (ko) 이미다졸 화합물 및 그의 의약 용도
JP2007530648A (ja) Ｃｎｓ障害の処置のための、５−ｈｔ６受容体アンタゴニストとしての３−（（ヘテロ）アリールスルフォニル）−８−（（アミノアルキル）オキシ）キノリン
JP3218243B2 (ja) ベンズイミダゾール、その製造および使用法
WO2005044825A1 (fr) Composes de silicium et utilisations de ceux-ci
US5861394A (en) Use of N-substituted phenothiazines
CA2464997A1 (fr) Composes de silicium
WO1991017157A1 (fr) Derives de gamma-butyrolactol ether
EP0413343B1 (fr) Dérivés de furanne
US8044066B2 (en) Derivatives of pyrrolopyridine-2-carboxamides, preparation thereof and therapeutic application thereof
JP5159630B2 (ja) 縮環複素環誘導体
US5852204A (en) Pyrrolo 3,2-b-!-carbazoles and 1H 1!benzothieno 2,3-f! indoles having anti-tumor activity
WO2004113353A1 (fr) Derives d'aminothiazole contenant du silicium en tant qu'inhibiteurs de cdk
WO2005035541A1 (fr) Composes de silicium et utilisation de ceux-ci
US5409937A (en) Hexahydrofuro(2,3-b)furans as PAF antagonists
KR20130121891A (ko) Ｃｃｒ２의 4-치환된-사이클로헥실아미노-4-피페리디닐-아세트아미드길항제
US5866588A (en) Imidazopyridine derivatives
EP0502706A1 (fr) Dérivés de 1-oxa-2,9-diphényle-spiro[4.4]nonane comme antagonistes du PAF

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase